SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-19-224762
Filing Date
2019-08-20
Accepted
2019-08-20 06:41:04
Documents
13
Period of Report
2019-08-20
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d651081d8k.htm   iXBRL 8-K 28954
2 EX-99.1 d651081dex991.htm EX-99.1 16972
  Complete submission text file 0001193125-19-224762.txt   175393

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA aeri-20190820.xsd EX-101.SCH 3078
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE aeri-20190820_lab.xml EX-101.LAB 18138
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE aeri-20190820_pre.xml EX-101.PRE 11413
6 EXTRACTED XBRL INSTANCE DOCUMENT d651081d8k_htm.xml XML 3420
Mailing Address 4301 EMPEROR BOULEVARD SUITE 400 DURHAM NC 27703
Business Address 4301 EMPEROR BOULEVARD SUITE 400 DURHAM NC 27703 (919) 237-5300
AERIE PHARMACEUTICALS INC (Filer) CIK: 0001337553 (see all company filings)

IRS No.: 203109565 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36152 | Film No.: 191037846
SIC: 2836 Biological Products, (No Diagnostic Substances)
Assistant Director 1